A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Clinical trial NCT00306267 · TERMINATED

Trial details

NCT number: NCT00306267
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Anemia Cancer Epoetin Alfa

Start date: 2006-03-01
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.